Beta Bionics, Inc. (NASDAQ:BBNX)
| Market Cap | 796.32M-19.8% |
| Revenue (ttm) | 119.01M+52.5% |
| Net Income | -72.97M+0.5% |
| EPS | -1.68+1.2% |
| Shares Out | 44.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,139.755 |
| Open | 18.07 |
| Previous Close | 18.08 |
| Day's Range | 17.58 - 18.07 |
| 52-Week Range | 8.80 - 32.71 |
| Beta | 3.38 |
| Analysts | Buy |
| Price Target | 24.00(+35.59%) |
| Earnings Date | Oct 27, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About BBNX
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$BBNX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in BBNX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BBNX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BBNX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BBNX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| DME Channel | $20.41M | 63.76% |
| PBP Channel | $11.60M | 36.24% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BBNX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BBNX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BBNX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $25.39M |
| IWMiShares Russell 2000 ETF | $19.35M |
| VXFVanguard Extended Market ETF | $9.38M |
| TMSLT. Rowe Price Small-Mid Cap ETF | $5.61M |
| VTWOVanguard Russell 2000 ETF | $4.67M |
| SCHASchwab U.S. Small-Cap ETF | $4.40M |
Estimated from each fund’s disclosed top holdings × AUM
BBNX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BBNX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score